Cargando…

Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study

OBJECTIVES: Self-reported progression was evaluated as a predictor of survival in patients with metastatic gastrointestinal stromal tumor (GIST). METHODS: This is a follow-up of an open cohort study of Life Raft Group (LRG) members with a diagnosis of KIT-positive metastatic GIST receiving imatinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Call, Jerry, Scherzer, Norman J., Josephy, P. David, Walentas, Christopher
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846326/ https://www.ncbi.nlm.nih.gov/pubmed/19946763 http://dx.doi.org/10.1007/s12029-009-9111-x

Ejemplares similares

Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
por: Call, Jerry, et al.
Publicado: (2012)

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
por: Call, Jerry W., et al.
Publicado: (2019)

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: A case report
por: Bhattacharya, Sayantan, et al.
Publicado: (2008)

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
por: Call, Jerry W., et al.
Publicado: (2019)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
por: Katsumata, Ryo, et al.
Publicado: (2023)

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose
por: Hislop, Jennifer, et al.
Publicado: (2011)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
por: Hompland, Ivar, et al.
Publicado: (2016)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
por: Kang, Min Kyu, et al.
Publicado: (2019)

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib
por: Gao, Xiaodong, et al.
Publicado: (2016)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
por: Niikura, Ryota, et al.
Publicado: (2016)

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report
por: Hughes, Brett, et al.
Publicado: (2004)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
por: Bouché, Olivier, et al.
Publicado: (2018)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib
por: Chang, Shih-Chun, et al.
Publicado: (2016)

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
por: Yim, Eunjung, et al.
Publicado: (2018)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor
por: Liu, Xuechao, et al.
Publicado: (2022)

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
por: Cheng, Xiaobin, et al.
Publicado: (2021)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_202qkrmsi1hr3pnet6cro1ck4c